Syra Health Corp. (SYRA) ("Syra Health" or the "Company"), a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, announced today the pricing of its upsized initial public offering (the "IPO") of 1,615,000 units ("Units") at a public offering price of
The Company's Class A common stock is expected to begin trading on The Nasdaq Capital Market on
The Company intends to use the net proceeds of the IPO for marketing and sales, product development, research and development and other general corporate purposes including working capital, operating expenses and capital expenditures.
Kingswood, a division of Kingswood Capital Partners, LLC ("Kingswood"), is acting as sole bookrunner for the IPO.
The Registration Statement on Form S-1 (File No. 333-271622) relating to the securities being sold in the IPO was filed with the Securities and Exchange Commission ("SEC") and declared effective on
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Syra Health is a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions. Syra Health aims to achieve its goal by becoming a valuable partner to government, payers, providers, life sciences organizations, and academic institutions. Syra Health offers products and services in digital health, behavioral and mental health, population health management, health education, and healthcare workforce. For more information, please visit www.syrahealth.com.
Kingswood
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates, expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the IPO on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For Underwriter Inquiries:
Managing Director
Kingswood US
561-702-4331
bherman@kingswoodus.com
For Media Inquiries:
Communications and Marketing Director
Syra Health Corp.
463-345-5180
christined@syrahealth.com
For Investor Inquiries:
Vice President
Lytham Partners, LLC
646-829-9701
shamsian@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-corp-announces-pricing-of-upsized-initial-public-offering-301942511.html
SOURCE Syra Health Corp.